FindTrial
Sign In

genetic screening for hereditary hemorrhagic telangiectasia

Investigation and applyling on the genetic screening kit for hereditary hemorrhagic telangiectasia

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900027420
Enrollment
Unknown
Registered
2019-11-12
Start date
2018-01-01
Completion date
Unknown
Last updated
2019-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hereditary hemorrhagic telangiectasia

Interventions

Gold Standard:Clinical outcomes
Index test:To&#32
identified&#32
the&#32
pathogenic&#32
variant&#32
through&#32
genetic&#32
testing&#32
for&#32
coding&#32
region&#32
of&#32
ENG,&#32
ACVRL1,&#32
SMAD4&#32
and&#32
BMP9.

Sponsors

Beijing Institute of Otolaryngology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Recurrent epistaxis; 2. The presence of mucocutaneous telangiectasias; 3. Ateriovenous malformations (AVMs) in internal organs; 4. Family history of HHT; 5. Unexplained recurrent hemoptysis or gastrointestinal bleeding.

Exclusion criteria

Exclusion criteria: Subjects were excluded if they or their first degree family members had any inherited vascular diseases and epistaxis with other causes.

Design outcomes

Primary

MeasureTime frame
mutation;—

Countries

China

Contacts

Public ContactYali Zhao

Beijing Institute of Otolaryngology

hollyzyl@126.com+86 15101012868

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026